My GMU Econ colleague Dan Klein eloquently makes the case for human-challenge trials.
While the removal of these import duties is great news, we have miles of regulatory roadblocks to remove before we sleep. Companies need approval from the National Institute of Virology regarding the efficacy of the testing kits and an import licence from the Drugs Controller General of India. Many companies have the approval or the licence, but not both. Once again, the unseen effect of cumbersome regulation has become visible, as government hospitals cannot procure tests for covid-19. Now that it has been seen that these regulations can threaten lives, the government has to clear many such thickets of regulation.
Joakim Book applauds the WHO for recognizing that diseases can be mitigated by individual freedom.
David Henderson is correct, and more than just marginally so.
I just ordered a copy of my Mercatus Center colleague Adam Thierer’s new book, Evasive Entrepreneurs.